Tarsus Pharmaceuticals, Inc. TARS EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s EPS (diluted)?
- Tarsus Pharmaceuticals, Inc. (TARS) reported EPS (diluted) of -$0.16 in Q1 2026.
- How has Tarsus Pharmaceuticals, Inc.'s EPS (diluted) changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s EPS (diluted) increased by 75.0% year-over-year, from -$0.64 to -$0.16.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s EPS (diluted)?
- Over 4 years (2021 to 2025), Tarsus Pharmaceuticals, Inc.'s EPS (diluted) has grown at a 22.3% compound annual growth rate (CAGR), from -$0.72 to -$1.61.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.